Rare Lymphomas

Current Management of Nasal NK/T-cell Lymphoma
April 15, 2010
ByWing Y. Au, MD

With better disease definition, staging, and monitoring, treatment of extranodal NK/T-cell lymphoma is becoming more rational. A large proportion of patients with localized nasal disease may enjoy prolonged disease-free survival. On the other hand, early HSCT or novel therapy may be recommended for aggressive extranasal disease.

Nasal NK/T-cell Lymphoma: Where Are We Now?
April 15, 2010
ByMary Jo Lechowicz, MD

Since the creation of the World Health Organization’s nasal natural killer (NK)/T-cell lymphoma category, the attempt to further classify, describe, and improve treatment in this entity has been underway. There has been quite a bit of confusion and frustration regarding diagnosis, staging, and treatment approaches. With his article in this issue of ONCOLOGY, Dr. Au has attempted to improve our knowledge of current approaches to NK/T-cell lymphomas, providing a thorough and contemporary review of the clinical management of these difficult tumors. The following commentary reflects a deep appreciation for the author’s work and expands upon a few points not previously highlighted.

Adult Burkitt Lymphoma: Advances in Diagnosis and Treatment
November 30, 2008
ByIbrahim T. Aldoss, MD|Dennis D. Weisenburger, MD|Kai Fu, MD, PhD|Wing C. Chan, MD|Julie M. Vose, MD, MBA|Philip J. Bierman, MD|R. Gregory Bociek, MD, MSc|James O. Armitage, MD

Burkitt lymphoma (BL) is a unique B-cell lymphoma characterized by a high proliferation rate and cytogenetic changes related to c-myc proto-oncogene overexpression. Burkitt lymphoma is a highly aggressive B-cell lymphoma that is most frequently seen in children and young adults in endemic areas.